The cost-effectiveness of an extended course (12 + 12 Weeks) of varenicline compared with other available smoking cessation strategies in the United States: An extension and update to the BENESCO model

Value in Health

Volumn 13, Issue 2, 2010, Pages 209-214

  Knight, Chris ^a   Howard, Paul ^a   Baker, Christine L ^b   Marton, Jeno P ^b  

^a Heron Evidence Development Ltd   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Cost effectiveness; Extended course; Maintenance therapy; Smoking cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; NICOTINE; VARENICLINE;

ADULT; AGED; ARTICLE; BENEFITS OF SMOKING CESSATION ON OUTCOMES MODEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MONEY; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; UNITED STATES;

EID: 77149151846     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00672.x     Document Type: Article

References (30)

1. Ezzati M, Lopez AD. Regional, disease specific patterns of smoking-attributable mortality in 2000. Tob Control 2004 13 : 388 395.
2. Eddy DM. Eddy ranks the tests. Harvard Health Letter 1992 Suppl. 10 1.
3. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004 3 : CD000146. DOI: 10.1002/14651858.CD000146.pub2.
4. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007 31 : CD000031.
5. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an 42 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 2006 296 : 47 55.
6. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007 6103 : CD006103.
7. Jorenby DE, Taylor Hays J, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006 296 : 56 63.
8. Howard P, Knight C, Boler A, et al. Cost-Utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model. Pharmacoeconomics 2008 26 : 497 511.
9. Varenicline for smoking cessation TA123. Technology appraisal. July 2007. Available from: http://www.nice.org.uk/TA123 [Accessed November, 2007 S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation. JAMA 2006 296 : 64 71.
10. Orme ME, Hogue SL, Kennedy LM, et al. Development of the health and economic consequences of smoking interactive model. Tob Control 2001 10 : 55 61.
11. Population Division, US Census Bureau. Table 1: Annual Estimates of the Population by Sex and Five-Year Age Groups for the United States: April 1, 2000 to July 1, 2004 (NC-EST2004-01).
12. National Health Interview Survey. National Center for Health Statistics. Available from: http://www.cdc.gov/nchs/data/nhis/earlyrelease/200512-08.pdf [Accessed March 27, 2007 M, Stanford R, Borker R. The burden of COPD in the USA: results from the Confronting COPD survey. Respir Med 2003 97 (Suppl. S81 9.
13. Kutikova L, Bowman L, Chang S, et al. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 2005 50 : 143 154.
14. Tsevat J, Kuntz KM, Orav EJ, et al. Cost effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001 141 : 727 734.
15. Taylor TN, Davis P, Torner JC, et al. Lifetime costs of stroke in the United States. Stroke 1996 27 : 1459 1466.
16. Stanford R, McLaughlin T, Okamoto LJ. The cost of asthma in the emergency department and hospital. Am J Respir Crit Care Med 1999 160 : 211 215.
17. Fleming T, ed. Redbook: Pharmacy's Fundamental Reference (Red Book Drug Topics). PDR: Physicians Desk Reference. Montvale, NJ : Thomson PDR, 2005.
18. Fiscella K, Franks P. Cost effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counselling. JAMA 1996 275 : 1247 1251.
19. Tengs T, Lin T. A meta-analysis of quality of life estimates for stroke. Pharmacoeconomics 2003 21 : 191 200.
20. Spencer M, Briggs A, Grossman R, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005 23 : 619 637.
21. Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003 58 : 388 393.
22. Trippoli S, Vaiani M, Lucioni C, et al. Quality of life and utility in patients with non-small cell lung cancer. Pharmacoeconomics 2001 19 : 855 863.
23. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalogue of health-state quality factors. Med Decis Mak Pharmacoeconomics 2005 1993 : 89 102.
24. In: Hay JW, Sterling KL, eds. Cost-effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Pharmacoeconomics 23 : 133 141.
25. Duncan PW, Lai SM, Keighley J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology 2000 39 : 835 841.
26. Szende A, Svensson K, Stahl E, et al. Psychometric and utility-based measures of health status of asthmatic patients with different disease control level. Pharmacoeconomics 2004 22 : 537 546.
27. Thun MJ, Apicella LF, Henley SJ. Smoking vs. other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA 2000 284 : 706 712.
28. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006 24 : 1 19.
29. Gold MR, Siegel JE, Russell LB, et al. Cost Effectiveness in Health and Medicine. Oxford : Oxford University Press, 1996.
30. National Institute of Health and Clinical Excellence Guide to the methods of technology appraisal. Available from: http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf [Accessed March 6, 2009 ].